Biogen Inc. (BIIB)

Market Cap	33.32B
Revenue (ttm)	9.66B
Net Income (ttm)	1.17B
Shares Out	145.60M
EPS (ttm)	8.01
PE Ratio	28.57
Forward PE	14.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	860,143
Open	232.03
Previous Close	231.77
Day's Range	225.10 - 233.18
52-Week Range	189.44 - 287.60
Beta	-0.02
Analysts	Buy
Price Target	286.78 (+25.33%)
Earnings Date	Jul 23, 2024

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Employees: 7,570
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB

Financial Performance

In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.

Analyst Forecast

According to 23 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $286.78, which is an increase of 25.33% from the latest price.

Price Target

$286.78

(25.33% upside)

Analyst Consensus: Buy